New drug study offers hope for chinese patients with severe bowel disease
NCT ID NCT07302360
Summary
This study aims to see how well the drug guselkumab works for people in China with moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease. It will follow 200 patients who are starting this type of medication for the first time, observing their symptoms, quality of life, and treatment patterns over 48 weeks in a real-world clinic setting, not a tightly controlled trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Hospital of Hebei Medical University
RECRUITINGShijiazhuang, 050000, China
Conditions
Explore the condition pages connected to this study.